The lowering of the price target by Goldman Sachs suggests a less optimistic view on Maravai LifeSciences' future performance, which could lead to a negative short-term impact on the stock price. The Neutral rating indicates no strong buy or sell recommendation, but the reduced price target may influence investor sentiment negatively.